FUTURE STRATEGY

A MESSAGE FROM CO-DIRECTOR RESEARCH (RADIATION MEDICINE), A/PROF JONATHAN RAMSAY

Icon Group will continue to invest in clinical trials and research and lead the way in providing access to new and emerging treatments to turn the dial on oncology treatment and beyond. Future direction will see a focus on new personalised treatments and precision medicine, the ongoing exploration of revolutionary Real World Data and the continued expansion of the Group’s international trials portfolio.

As Co-Director of Research I’m looking forward welcoming new leadership and continuing to onboard more trials, investigators, and partnerships. I’m particularly excited for the next five years as we embark on an ambitious strategic plan which will drive forward our reach and capability to provide access to more trials and ultimately new and exciting treatments.

Together we’re committed to changing the face of cancer care and contributing to advancements in global healthcare so people can share in more memories and live their best possible lives.

A/PROF JONATHAN RAMSAY

Theranostics

There will be a continued focus of embedding Icon’s global Theranostics Program with a comprehensive clinical trial and registry program. Icon aims to be a provider of choice for theranostics research initiatives alongside the expansion of the group’s trial capabilities and offering.

Real World Data

In 2022, Icon Group commenced an initiative researching how the organisation can use Real World Data (RWD) to provide better treatment opportunities for Icon patients. RWD provides evidence of the usage and potential benefits or risks of a medical product. Common sources include electronic health records (EHRs), hospital episode data, claims data (PBS and MBS) and patient registry data (product and disease), chart reviews, clinical audits, and observational cohorts. RWD is an evidence base made available from clinical trials and research projects to provide a more complete picture of treatment effectiveness and safety within a real-world patient population.

The advantages of RWD compared with normal clinical trials are that they are conducted often without the need for patient recruitment, allow safe research on high-risk groups and facilitate rapid access for data retrieval. Combined with clinical trial data, RWD can

New Geographies

There will be a continued focus on expanding Icon’s highly regarded clinical trials capabilities in more Icon Group locations. The Group’s mature research operations allow for efficient and effective growth opportunities in existing centres as well as new be used to support claims of efficacy or safety in reimbursement applications, regulatory approvals or monitor outcome in the post-marketing setting. It is often used in situations where the data is scarce or where clinical trials are not feasible or ethical (e.g., rare diseases and paediatric populations). locations beyond Australian shores. This will see Icon focus on activating new trials and research projects in Singapore and the wider ASEAN region and grow alongside the Group’s services into new geographies.

Icon will seek further opportunities to establish clinical and technical experience in medical physics, dosimetry, radiochemistry, and operations to support theranostics services and set the agenda to deliver high quality theranostics trial operations globally.

A dedicated team has been created to identify the data that the organisation collects, provide an additional layer to ensure the accuracy and completeness and then report on these datasets to provide Icon with a greater understanding of the Icon Cancer Centre patient population in addition to participation in Phase IV studies, observational studies, and other Real World Evidence opportunities. The intent of this initiative is to ensure that Icon Group’s mission is more effectively delivered by further understanding the complete patient experience outside of the routine care pathway or clinical trial participation.

Theranostics Real World Data New Geographies